DiFusion Formed New Board to Scale Biomaterials
The Austin-based medical company is shifting focus from development to commercial scaling and infrastructure growth.
Updated on Sept. 30, 2026 in People
Live Poll
Should companies be allowed to promote pre-clinical research results that lack final regulatory approval?
Austin-based DiFusion Therapeutic Biomaterials has activated a five-member operating board to oversee the transition of its ZFUZE platform from clinical validation to commercial expansion. The board is designed for active execution across clinical, capital, and product development functions.
Why it matters
This move marks a shift for the local firm as it looks to scale its therapeutic biomaterials platform. The company is currently advancing new pipelines for peptide-functionalization and therapeutic ions to expand its market reach.
DiFusion has surpassed 5,500 procedures with its ZFUZE devices and holds two FDA Master Files alongside two 510(k) clearances. The impact of the new five-member board on future OEM conversion rates remains to be seen.
The players
Kevin Cordell
He serves as the chairman of the new DiFusion operating board.
DiFusion Therapeutic Biomaterials
An Austin-based company that develops medical devices and therapeutic biomaterials.
The details
The newly activated board includes Kevin Cordell as chairman, alongside members Michael Callahan, Stephen Bartol, Dan George, and Derrick Johns. The team is structured to prioritize active execution in OEM licensing and capital formation rather than passive oversight. DiFusion utilizes a non-exclusive OEM licensing model and is currently scaling its infrastructure to support expanded therapeutic applications.
Timeline
2017: Sentio was acquired by Johnson & Johnson.
July 2025: A manufacturing-process patent application was published.
September 30, 2026: DiFusion announced the activation of the operating board.
The Texas Context
This move follows the 2017 acquisition of Sentio by Johnson & Johnson, reflecting the ongoing maturation of the Austin medical device sector. The company's focus on scaling indicates a drive to establish a deeper manufacturing and licensing footprint within the region.
For Austin residents and investors, this activation signals a shift toward larger-scale hiring and potential infrastructure expansion at the company's local headquarters. Future growth will be tied to the successful conversion of OEM licensing deals and ongoing testing of peptide technology.
The takeaway
DiFusion is pivoting from research to an active, board-led scaling phase to increase its footprint in therapeutic biomaterials. Watch for developments in their peptide-functionalization pipeline as they scale their OEM licensing model.
Further reading
Learn more about local industry moves in our People section.
Live Poll
Should companies be allowed to promote pre-clinical research results that lack final regulatory approval?
